Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › crizotinib

crizotinib

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of crizotinib

24 trials tracked of crizotinib: 3 in phase 3 or 4 and 3 with published results. The most-cited published study has 990 citations.

24Trials tracked
3Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 3 3 Phase 2 9 Phase 1 8 Other / NA 4
  1. Phase 3 ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants Completed · 990 cited
  2. Phase 3 A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants Completed · 703 cited
  3. Phase 3 A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients Completed · 186 cited
  4. Phase 2 Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy Completed
  5. Phase 2 Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma Completed
  6. Phase 2 Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer Completed
Show 18 more trials
  1. Phase 2 Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Completed
  2. Phase 2 A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) Completed
  3. Phase 2 Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed Completed
  4. Phase 2 Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas Completed
  5. Phase 2 A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations Completed
  6. Phase 2 Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC Completed
  7. Phase 1 A Phase 1 Absolute Bioavailability Study For Oral Crizotinib In Healthy Volunteers Completed
  8. Phase 1 Relative Bioavailability Of A Crizotinib Oral Liquid Formulation To Crizotinib Formulated Capsule Completed
  9. Phase 1 Bioequivalence And Food Effect Study Comparing The Commercial Formulation Of Crizotinib To Its Clinical Study Formulations And Commercial Formulation With Or Without Food In Healthy Volunteers Completed
  10. Phase 1 Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients Completed
  11. Phase 1 A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors Completed
  12. Phase 1 Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Completed
  13. Phase 1 Estimation Of Effect Of Ketoconazole On Pharmacokinetics Of Crizotinib In Healthy Volunteers Completed
  14. Phase 1 Estimation Of Effect Of Rifampin On Pharmacokinetics Of Crizotinib In Healthy Volunteers Completed
  15. N/A Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials Completed
  16. N/A Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers. Completed
  17. N/A Study to IDEntify Patients With Advanced/Metastatic Non Small Cell Lung Cancer (NSCLC) and ALK and ROS1 Translocation and to Establish Their Therapeutic Management (IDEALK&ROS) Completed
  18. N/A A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. Completed

Showing the 24 most-cited and recently-updated of 24 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
mRNA vaccines reshape tumor microenvironment and induce durable anti-tumor immunity in lung cancer
Allergy & Immunology Sys. Review
mRNA vaccines reshape tumor microenvironment and induce durable anti-tumor immunity in lung cancer mRNA Vaccines Show Promise for Lung Cancer Treatment
This systematic review examines the current status and prospects of mRNA vaccines for lung cancer. The authors synthesize evidence that mRNA…
New research explores how mRNA technology can reshape the tumor environment and trigger immune responses to fight lung cancer.
Frontiers Aug 26, 2026
Alectinib improves progression-free survival over crizotinib in ALK-positive NSCLC (HR 0.41)
Oncology Phase III
Alectinib improves progression-free survival over crizotinib in ALK-positive NSCLC (HR 0.41) Alectinib Shows Better Progression-Free Survival Than Crizotinib for NSCLC
This pooled analysis of Phase III trials involving 500 patients with ALK-positive NSCLC found that alectinib significantly improved progress…
Alectinib showed better progression-free survival than crizotinib in a study of 500 patients with ALK-positive lung cancer.
Jul 27, 2026
ALK tyrosine kinase inhibitors achieve 58.5% objective response rate in ALK-positive non-small cell lung cancer
Oncology Meta-analysis
ALK tyrosine kinase inhibitors achieve 58.5% objective response rate in ALK-positive non-small cell lung cancer New data shows how ALK inhibitors treat lung cancer
This meta-analysis of 6382 adults with ALK-positive non-small cell lung cancer (NSCLC) found an overall objective response rate (ORR) of 58.…
Recent analysis shows that newer generations of targeted drugs offer significant response rates for patients with specific types of lung can…
Jul 3, 2026